Shenzhen J.ale Bio Cervical Sample Collector Launched

After 1 year of hard work, all staff of Shenzhen J.able Bio Co., Ltd. have continuously selected raw materials for the product cervical sample collector, changed the design, tested the usability and safety of the product, sent the sample for inspection, and verified the product quality, etc., finally now, in June, 2022, we obtained the China Class II medical device registration certificate and was successfully listed,CFDA.

The cervical sample collector is mainly used to collect cervical epithelial cells, cell clusters and cell masses. It is also commonly known as HPV gynecological cervical cancer screening.

So what is cervical cancer and why should we do cervical cancer screening?

What is cervical cancer

Cervical cancer is currently the only gynecological cancer with a clear etiology. Its etiology is caused by persistent infection of high-risk HPV (human papillomavirus) virus, which is closely related to sexual life. Women who have sex too early are an important factor in increasing the incidence of cervical cancer. One of the factors; if you do not pay attention to sexual hygiene or unclean sexual life, multiple sexual partners will increase the incidence of cervical cancer. Current research shows that more than 95% of cervical cancer patients carry HPV, therefore, it is considered to be the culprit of cervical cancer.

Cervical cancer is not an incurable disease. If it can be detected early, the cure rate of the disease is very high, and the progress of the disease is very slow. It usually takes years or even decades from being infected by a virus to finally becoming cancerous. Therefore, early detection and early detection is very important.

Causes of Cervical Cancer

Did you know? More than 95% of cervical cancers are caused by high-risk HPV infection. At present, there are more than 120 known HPV types, more than 30 types are related to reproductive tract infections, of which more than 10 types are related to cervical intraepithelial neoplasia (CIN) and cervical cancer are closely related. Medical research has found that more than 99% of cervical cancer tissues have high-risk HPV infection.

Cervical Cancer Screening

As long as women start having sex, they are likely to be infected with HPV (human papilloma virus, the main cause of cervical cancer). How to do cervical cancer screening? Cervical cancer screening should adopt a “three-step” procedure of cervical cytology or high-risk HPV DNA detection, colposcopy, and cervical biopsy. The diagnosis is based on histological diagnosis.

1. Cervical cytology

Compared with high-risk HPV detection, cytology has high specificity but low sensitivity. Screening should start 3 years after sexual activity, or after age 21, and review regularly.

2. High-risk HPV DNA testing

Compared with cytology, it has higher sensitivity and lower specificity. Can be used in combination with cytology for cervical cancer screening. It can also be used for the triage of abnormal cytology. When the cytology is atypical squamous cells of undetermined significance (ASCUS), high-risk HPV DNA testing is performed. Colposcopy is performed for positive patients, and cytology after 12 months for negative patients.

3. Colposcopy

If cytology is atypical squamous cells (ASCUS) and high-risk HPV DNA test is positive, or low-grade squamous intraepithelial lesions and above, colposcopy should be performed.

Cervical Cancer Prevention

There are no clinical symptoms in the precancerous lesions of the cervix and in the early stage, and most of them are in the advanced stage when symptoms appear. Therefore, regular cervical cancer screening is very helpful for cervical cancer prevention. The medical community recognizes that the mature examination methods for cervical cancer are TCT (liquid-based cytology test) and HPV (human papillomavirus) detection, both of which are carried out by extracting secretions from the cervical canal, collecting more cells than cervical smears. The combined detection rate of cervical precancerous lesions is over 90%.

The prevention of cervical cancer focuses on examination. As long as women who have sex are likely to get cervical cancer, according to the age distribution of patients, it is recommended to carry out cervical cancer screening from the age of 25 to 70, or from having sex for 3 years. Then start screening.

If economic conditions permit, gynecological examinations after the age of 25 can perform HPV and TCT examinations at the same time; if economic conditions are average, HPV should be done at least every three years, and TCT should be checked after positive detection. If TCT does not reveal precancerous lesions , you can wait six months to check high-risk HPV; if both TCT and HPV are normal, you can check every 5 years until the age of 70.


Post time: Jul-05-2022